Short Interest in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Decreases By 24.7%

01 May 2026, 18:49 by Teresa Graham · The Cerbat Gem

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 48,120 shares, a decrease of 24.7% from the March 31st total of 63,946 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily trading volume, of 25,429 shares, the short-interest ratio is presently 1.9 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BNR shares. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Stock Report on Burning Rock Biotech

Insider Buying and Selling at Burning Rock Biotech

In related news, Director Yusheng Han purchased 314,870 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were bought at an average price of $17.36 per share, for a total transaction of $5,466,143.20. Following the purchase, the director directly owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. This represents a 1.81% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 30.30% of the stock is owned by insiders.

Institutional Trading of Burning Rock Biotech

Several institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Burning Rock Biotech in the 3rd quarter worth $26,000. Prospera Financial Services Inc boosted its stake in shares of Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the last quarter. Marshall Wace LLP bought a new position in Burning Rock Biotech in the 4th quarter worth $220,000. Finally, Crcm LP raised its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the period. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Burning Rock Biotech Trading Up 0.5%

BNR traded up $0.09 during trading on Friday, hitting $17.09. 38,332 shares of the company’s stock traded hands, compared to its average volume of 29,033. The company’s 50 day simple moving average is $20.10 and its two-hundred day simple moving average is $20.74. Burning Rock Biotech has a 12-month low of $2.18 and a 12-month high of $41.72. The stock has a market capitalization of $183.89 million, a price-to-earnings ratio of -21.63 and a beta of 1.59.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%. The business had revenue of $18.05 million for the quarter.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.